Skip to main content

Real-World Effectiveness of SGLT2i on Incident Kidney Outcomes in Patients With Type 2 Diabetes and Normoalbuminuria-A Territory-Wide Retrospective Study

In brief

SGLT2 inhibitors linked to 38% lower kidney risk in diabetes with normal albumin

In a real-world study of 226,434 people with type 2 diabetes and normal urine albumin, sodium-glucose cotransporter 2 inhibitor use was associated with 38% lower risk of sustained kidney function loss or end-stage kidney disease over a median 7.2 years. Developing albuminuria nearly doubled risk, but the observational findings cannot establish that treatment caused the lower risk.

Journal
Diabetes, obesity & metabolism (Q1)
Published
19 November 2026
Study design
Cohort / observational study
Evidence level
Level 3, Low (CEBM 3b)
Authors
Yuheng Zhang, David Tak-Wai Lui, Kelly Hiu-Ching Wong, Ivan Kwok-Ming Ma, Carol Ho-Yi Fong, Wing-Sun Chow, et al.
PMID
43058081
DOI
10.1111/dom.71553

Why clinicians should know about it

  • Picked for Internal Medicine (paper of the day, 22 November 2026): SGLT2 inhibitors and kidney outcomes in type 2 diabetes

Abstract

AIMS: Normoalbuminuric chronic kidney disease (NACKD) is increasingly prevalent in Type 2 diabetes (T2D). Here, we evaluated the kidney effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among T2D patients with baseline normoalbuminuria, taking into consideration their interim development of albuminuria, a risk factor for kidney function decline. MATERIALS AND METHODS: Using a real-world territory-wide electronic health record database, T2D patients with normoalbuminuria between January 2015 and December 2019 were identified. Incident kidney outcome was defined as a composite of sustained ≥ 40% decline in eGFR or end-stage kidney disease. Time-dependent Cox regression was used to evaluate the kidney effects of SGLT2i, modelling SGLT2i use and interim albuminuria status as time-varying covariates. Conditional logistic regression with time-dependent propensity score matching (TDPSM) was conducted to further evaluate the effects of SGLT2i in NACKD patients. RESULTS: Among the 226 434 T2D patients with baseline normoalbuminuria, over a median follow-up of 7.17 years (IQR: 5.50-8.17), use of SGLT2i (HR, 0.62, 95% CI, 0.57-0.66; p < 0.001) and interim development of albuminuria (HR, 1.90, 95% CI, 1.84-1.96; p < 0.001) were independently associated with incident kidney outcome, which remained statistically significant in subgroup and sensitivity analyses. In TDPSM, use of SGLT2i was associated with a lower risk of incident kidney outcome among NACKD patients (OR, 0.61, 95% CI, 0.49-0.77; p < 0.001). CONCLUSIONS: In T2D patients with normoalbuminuria, regardless of the presence of CKD, SGLT2i use was associated with a significantly lower risk of incident kidney outcome.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.